Definitive radiotherapy with concurrent oncothermia for stage IIIB non‑small‑cell lung cancer: A case report

Yeo,Seung‑Gu

doi:10.3892/etm.2015.2567

Definitive radiotherapy with concurrent oncothermia for stage IIIB non‑small‑cell lung cancer: A case report

Authors:
- Seung‑Gu Yeo
View Affiliations

Affiliations: Department of Radiation Oncology, Soonchunhyang University College of Medicine, Soonchunhyang University Hospital, Cheonan 330‑721, Republic of Korea
Published online on: June 11, 2015 https://doi.org/10.3892/etm.2015.2567
Pages: 769-772

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hyperthermia enhances the susceptibility of tumors to radiotherapy (RT) and chemotherapy. Oncothermia, also known as electro‑hyperthermia, is a new treatment modality developed to overcome the problems of traditional hyperthermia by selectively delivering energy to the malignant tissues. The present study reports the outcome of combined oncothermia and RT in a 75‑year‑old patient with stage IIIB non‑small‑cell lung cancer (NSCLC). Due to the advanced age and the performance status of the patient, the combination of systemic chemotherapy and RT was deemed infeasible; therefore, the patient instead decided to undergo oncothermia concurrently with definitive RT. The RT was administered at a dose of 64.8 Gy in 36 fractions using a three‑dimensional conformal plan technique. Oncothermia was started concomitantly with RT and was performed for 60 min per session, two sessions per week, for a total of 12 sessions. No severe toxicities developed, with the exception of mild odynophagia, which resolved soon after the treatments. Follow‑up computed tomography showed complete tumor response, and the patient was alive with no evidence of the disease 18 months after the completion of the treatment. In conclusion, the present case report suggests that oncothermia combined with RT, with the former possessing radiosensitizing potential and no additional toxicities, may be a promising alternative for advanced‑age and/or frail patients with locally advanced NSCLC.

View Figures

View References

1	Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH and Lee JS: Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat. 46:124–130. 2014. View Article : Google Scholar : PubMed/NCBI
2	William WN Jr, Lin HY, Lee JJ, Lippman SM, Roth JA and Kim ES: Revisiting stage IIIB and IV non-small cell lung cancer: Analysis of the surveillance, epidemiology and end results data. Chest. 136:701–709. 2009. View Article : Google Scholar : PubMed/NCBI
3	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L: International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
4	Russell K, Healy B, Pantarotto J, Laurie SA, MacRae R, Sabri E and Wheatley-Price P: Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer. Clin Lung Cancer. 15:237–243. 2014. View Article : Google Scholar : PubMed/NCBI
5	Laine AM, Westover KD and Choy H: Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. Semin Oncol. 41:57–68. 2014. View Article : Google Scholar : PubMed/NCBI
6	Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
7	Hegyi G, Szigeti GP and Szász A: Hyperthermia versus oncothermia: Cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med. 2013:6728732013. View Article : Google Scholar : PubMed/NCBI
8	Andocs G, Szasz O and Szasz A: Oncothermia treatment of cancer: From the laboratory to clinic. Electromagn Biol Med. 28:148–165. 2009. View Article : Google Scholar : PubMed/NCBI
9	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th. Springer; New York, NY: 2010
10	Coffey DS, Getzenberg RH and DeWeese TL: Hyperthermic biology and cancer therapies: A hypothesis for the ‘Lance Armstrong effect’. JAMA. 296:445–448. 2006. View Article : Google Scholar : PubMed/NCBI
11	Roti Roti JL: Cellular responses to hyperthermia (40–46 degrees C): Cell killing and molecular events. Int J Hyperthermia. 24:3–15. 2008. View Article : Google Scholar : PubMed/NCBI
12	Halperin EC, Brady LW, Perez CA and Wazer DE: Perez and Brady's Principles and Practice of Radiation Oncology. 6th. Lippincott Williams & Wilkins; Baltimore, MD: 2013
13	van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL and Hart AA: Dutch Deep Hyperthermia Group: Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Lancet. 355:1119–1125. 2000. View Article : Google Scholar : PubMed/NCBI
14	Sauer R, Creeze H, Hulshof M, Issels R and Ott O: Interdisciplinary Working Group for Clinical Hyperthermia (Atzelsberg Circle) of the German Cancer Society and the German Society of Radiooncology: Concerning the final report ‘Hyperthermia: A systematic review’ of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010. Strahlenther Onkol. 188:209–213. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wild C: Should hyperthermia be included in the benefit catalogue for oncologic indications? Commercial interests are presumed behind the editorial of R. Sauer et al. Strahlenther Onkol. 189:81–86. 2013. View Article : Google Scholar : PubMed/NCBI
16	Szasz A: Current status of oncothermia therapy for lung cancer. Korean J Thorac Cardiovasc Surg. 47:77–93. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kim MJ, Yeo SG, Kim ES, Min CK and Se An P: Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer. Oncol Lett. 5:840–844. 2013.PubMed/NCBI
18	Yeo SG and Kim ES: Efficient approach for determining four-dimensional computed tomography-based internal target volume in stereotactic radiotherapy of lung cancer. Radiat Oncol J. 31:247–251. 2013. View Article : Google Scholar : PubMed/NCBI
19	Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W and Cox JD: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst. 103:1452–1460. 2011. View Article : Google Scholar : PubMed/NCBI
20	Bayman N, Blackhall F, McCloskey P, Taylor P and Faivre-Finn C: How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer? Lung Cancer. 83:117–125. 2014. View Article : Google Scholar : PubMed/NCBI
21	Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van der Velden J, Burger C, van der Wilt CL, et al: First results of triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia for the treatment of patients with stage IIB, III and IVA cervical carcinoma. Cancer. 104:763–770. 2005. View Article : Google Scholar : PubMed/NCBI